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size. Mean size at intervention was 2.2 cm (range, 0.8-
3.7). Fifteen patients underwent open repair while 28
(including all ruptures) underwent EV embolization (n ¼
26) or covered stent exclusion (n ¼ 2). In the open surgical
cohort seven patients underwent aneurysmectomy, while
eight underwent aneurysmectomy with splenectomy. In
the elective EV cohort technical success was noted in all
patients; both patients managed for rupture required either
intra-operative or delayed conversion to splenectomy for
hemodynamic instability and splenic infarction respectively.
No major operative morbidity or mortality was identiﬁed
following elective open or EV repair. No recurrence, aneu-
rysm-related mortality or major morbidity was identiﬁed
during a mean follow-up of 42 months (range, 0-89).
Conclusions: This contemporary experience is com-
parable to our historical experience in female predomi-
nance, aneurysm size at intervention, and postoperative
morbidity and mortality justifying the current EV
approach. There has been a reduction in grand multiparity
by half (25% to 13%). Rupture remains a recognized risk
which carries notable morbidity and mortality.
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Objectives: The endovascular management of athero-
sclerotic renal artery stenosis (RAS) has evolved over
several decades. Endovascular therapy with stents (PTAS)
often utilizes balloon-expandable bare-metal stents due to
their radial force. However, restenosis frequently occurs.
No studies have investigated the patency of covered stents
in comparison to bare-metal stents in the treatment of
RAS.
Methods: We performed a retrospective chart review
of 197 patients at our institution who underwent renal
artery stenting for atherosclerotic RAS from 2005-2011.
179 patients were included with a total of 206 stented renal
arteries and 226 PTAS interventions. Index cases as well as
ﬁrst and second reinterventions were examined.
Results: 179 patients were included in the study with
a total of 226 interventions performed with PTAS. Of these
interventions, 195 were index (ﬁrst) procedures. 20 PTAS
were in vessels which had required one previous interven-
tion and 11 PTAS were in vessels that required two
previous interventions. The average follow-up was 30
months. 48 vessels were treated with angioplasty and
covered stents and 178 vessels were treated with angio-
plasty and bare-metal stents. 4 of 48 (8.3%) in the covered
stent group and 41 vessels of 178 (23%) in the bare-metalstent group developed restenosis requiring intervention.
Primary patency for covered stents was 100% at 12 months
and 93% at 24 months; bare metal stent patency was 83% at
12 months and 74% at 24 months. There was a statistical
signiﬁcance in patency in comparing covered stents to
bare-metal stents with P < .045 in the overall study.
Conclusions: While initial success was seen in treat-
ing RAS with bare-metal stents, covered stents confer
increased primary patency and decreased need for repeat
secondary interventions. Covered stents should be
considered in renal artery stenting for both primary index
procedures and secondary interventions due to their
improved performance over bare-metal stenting for ostial
RAS.
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Objectives: Carotid interventions have been shown to
decrease stroke risk and improve cerebral perfusion.
However, nearly 40% of patients who undergo carotid
revascularization procedures experience cognitive deterio-
ration. We have demonstrated that subclinical microembo-
lization is associated with memory decline. The role of
genetic factors in cognitive function is unclear. We herein
seek to assess genetic determinants as potential risk factors
for these procedures.
Methods: Over one year period, patients undergoing
carotid interventions at a single academic institution were
recruited to participate. Patients underwent neuropsycho-
logical testing two weeks prior to and at one month
following their procedure and MRI prior to and within
48 hours following their procedure. Saliva samples were
collected for genetic testing and demographics were
recorded. Logistic regressions were used to search for
associations.
Results: 34 patients were included (18 CAS, 16
CEA); all were male with a mean age of 68. The majority
of patients exhibit hypertension (94%) and have a history
